Skip to main content
Log in

Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna

  • Letter to the Editors
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff R, Salusky IB (2003) Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 18:1260–1264

    Article  PubMed  Google Scholar 

  2. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245–252

    CAS  Google Scholar 

  3. Salusky IB, Foley J, Nelson P, Goodman WG (1991) Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324:527–531

    CAS  PubMed  Google Scholar 

  4. Salusky IB, Kuizon BD, Belin T, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907–914

    CAS  PubMed  Google Scholar 

  5. Salusky IB, Goodman WG (2001) Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 12:1978–1985

    Google Scholar 

  6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942

    CAS  PubMed  Google Scholar 

  7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483

    CAS  PubMed  Google Scholar 

  8. Hergesell O, Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863–867

    Article  CAS  PubMed  Google Scholar 

  9. Joy MS, Finn WF (2003) Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96–107

    Article  CAS  PubMed  Google Scholar 

  10. Eknoyan G, Levin A, Levin NW (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease—foreword. Am J Kidney Dis 42:S7–S201

    Article  Google Scholar 

  11. Collins AJ, St.Peter WL, Dalleska FW, Ebben JP, Ma JZ (2000) Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 54:334–341

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Isidro B. Salusky.

Additional information

This reply refers to the Letter to the Editors at http://dx.doi.org/10.1007/s00467–004–1535–8

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salusky, I.B., Elashoff, R. Reply to the letter from J. I. Minguela and R. Ruiz-de-Gauna. Pediatr Nephrol 19, 947–948 (2004). https://doi.org/10.1007/s00467-004-1531-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-004-1531-z

Keywords

Navigation